Quick Answer
Transcode Therapeutics, Inc. reported Net Income of -$16.75 million for fiscal year 2024.
Transcode Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$16.75M | +9.7% |
| 2023 | -$18.55M | -5.6% |
| 2022 | -$17.56M | -156.7% |
| 2021 | -$6.84M | -192.0% |
| 2020 | -$2.34M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.86M | -109.2% | -13.6% |
| June 30, 2025 | -$4.28M | +17.6% | +64.6% |
| March 31, 2025 | -$12.09M | -263.3% | -420.6% |
| September 30, 2024 | -$2.32M | +56.2% | +55.3% |
| June 30, 2024 | -$5.19M | -19.6% | -56.0% |
| March 31, 2024 | -$3.33M | +30.9% | +37.2% |
| September 30, 2023 | -$5.30M | -23.6% | -22.1% |
| June 30, 2023 | -$4.34M | +7.1% | +9.9% |
- Transcode Therapeutics, Inc. showed an increase of +9.7% in Net Income compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s net income has declined by 614.8% (from -$2.34 million to -$16.75 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: